Raymond James Financial Inc. Takes Position in Ultralife Co. (NASDAQ:ULBI)
Raymond James Financial Inc. has acquired a new position in Ultralife Co. (NASDAQ:ULBI), purchasing 70,002 shares valued at approximately $522,000. This acquisition represents 0.42% of Ultralife's stock. Other institutional investors have also adjusted their stakes in the company. Ultralife's stock opened at $4.88, with a market cap of $81.17 million and a PE ratio of 8.87. The company reported $0.01 earnings per share for the last quarter, missing estimates, and had revenue of $43.85 million.
Raymond James Financial Inc. acquired a new position in Ultralife Co. (NASDAQ:ULBI - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 70,002 shares of the technology company's stock, valued at approximately $522,000. Raymond James Financial Inc. owned 0.42% of Ultralife at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. IFP Advisors Inc acquired a new position in Ultralife in the 4th quarter worth approximately $85,000. Barclays PLC raised its holdings in shares of Ultralife by 21.3% during the third quarter. Barclays PLC now owns 13,395 shares of the technology company's stock valued at $121,000 after acquiring an additional 2,355 shares during the last quarter. Jane Street Group LLC acquired a new stake in Ultralife during the 3rd quarter worth $166,000. Perritt Capital Management Inc grew its stake in Ultralife by 100.0% during the 4th quarter. Perritt Capital Management Inc now owns 30,000 shares of the technology company's stock valued at $224,000 after acquiring an additional 15,000 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Ultralife by 35.7% in the fourth quarter. Bank of New York Mellon Corp now owns 43,541 shares of the technology company's stock valued at $324,000 after purchasing an additional 11,448 shares in the last quarter. 30.68% of the stock is currently owned by institutional investors.
Ultralife Stock Performance
Shares of ULBI opened at $4.88 on Friday. The stock has a 50-day simple moving average of $4.97 and a 200-day simple moving average of $6.74. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.62 and a current ratio of 3.30. Ultralife Co. has a 1 year low of $4.07 and a 1 year high of $13.39. The stock has a market capitalization of $81.17 million, a PE ratio of 8.87 and a beta of 0.77.
Ultralife (NASDAQ:ULBI - Get Free Report) last released its quarterly earnings data on Tuesday, April 1st. The technology company reported $0.01 earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by ($0.14). The company had revenue of $43.85 million for the quarter, compared to analyst estimates of $40.00 million. Ultralife had a return on equity of 7.92% and a net margin of 5.44%. During the same period in the previous year, the business posted $0.18 EPS.
Analyst Ratings Changes
Separately, StockNews.com cut Ultralife from a "buy" rating to a "hold" rating in a report on Tuesday, March 18th.
Check Out Our Latest Research Report on ULBI
Ultralife Company Profile
(Free Report)Ultralife Corporation, together with its subsidiaries, designs, manufactures, installs, and maintains power, and communication and electronics systems worldwide. The company operates in two segments, Battery & Energy Products and Communications Systems. The Battery & Energy Products segment offers lithium 9-volt, cylindrical, thin lithium manganese dioxide, rechargeable, and other non-rechargeable batteries; lithium-ion cells, multi-kilowatt module lithium-ion battery systems, and uninterruptable power supplies; and rugged military and commercial battery charging systems and accessories, including smart chargers, multi-bay charging systems, and various cables.
Recommended Stories
- Five stocks we like better than Ultralife
- What is the MACD Indicator and How to Use it in Your Trading
- IBM's AI Offensive: Assessing IBM's Path to Renewed Growth
- Quiet Period Expirations Explained
- Rockwell Automation: Tailwinds From Onshoring U.S. Production
- Why Are These Companies Considered Blue Chips?
- Is Energy Transfer Undervalued or a Value Trap?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Ultralife Right Now?
Before you consider Ultralife, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultralife wasn't on the list.
While Ultralife currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
